Alkem Laboratories Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Alkem Laboratories' board approved strong Q1 FY26 results: Consolidated revenue jumped 11.2% YoY to ₹3,371.1 Cr. Net profit surged 21.8% to ₹664.3 Cr, while EBITDA rose 21.4% to ₹739.1 Cr, with margins improving to 21.9%. Domestic sales grew 12% to ₹2,265 Cr, outpacing the Indian market. International sales were also robust, up 8.9% to ₹1,053.9 Cr, including 8.8% US growth. Strategic acquisitions of Adroit Biomed (₹140 Cr) and Bombay Ortho (₹147 Cr) were also noted, plus a ₹14.29 Cr gain from an asset sale. #Alkem #Pharma